Literature DB >> 19874350

Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.

Y Teraki1, M Shibuya, S Izaki.   

Abstract

BACKGROUND: Drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is characterized by late disease onset, fever, rash, hepatic dysfunction, haematological abnormalities, lymphadenopathy and often, human herpesvirus (HHV) reactivation. The diagnosis of DIHS is based on the combined presence of these findings. Anticonvulsants are a major cause of DIHS and may also cause Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We examined whether SJS/TEN due to anticonvulsants display similar clinical and laboratory features seen in DIHS.
METHODS: Patients diagnosed with SJS or TEN due to anticonvulsants (n = 8) were examined and their clinical features and laboratory findings were compared with patients with anticonvulsant-related DIHS (n = 6).
RESULTS: Seven of the eight patients with SJS/TEN developed symptoms > 3 weeks after starting anticonvulsants. Hepatic dysfunction was present in six patients with SJS/TEN and five patients with DIHS. Leucocytosis and/or eosinophilia was noted in seven patients with SJS/TEN and four patients with DIHS. Only one patient in the SJS/TEN group had atypical lymphocytosis; this was present in four patients with DIHS. Reactivation of HHV-6 was detected in one of the four patients tested in the SJS/TEN group, although it was seen in five of the six patients with DIHS.
CONCLUSIONS: TSJS/TEN due to anticonvulsants may exhibit some clinical and laboratory features of DIHS. The nature of the cutaneous involvement should be emphasized in the diagnosis of DIHS.
© 2009 The Author(s). Journal compilation © 2009 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19874350     DOI: 10.1111/j.1365-2230.2009.03718.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  9 in total

1.  EMPACT syndrome: limited evidence despite a high-risk cohort.

Authors:  Andrew J Bishop; Maria Chang; Mario E Lacouture; Christopher A Barker
Journal:  J Neurooncol       Date:  2014-05-03       Impact factor: 4.130

Review 2.  Hair disorders in patients with cancer.

Authors:  Azael Freites-Martinez; Jerry Shapiro; Shari Goldfarb; Julie Nangia; Joaquin J Jimenez; Ralf Paus; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2018-04-14       Impact factor: 11.527

Review 3.  Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS.

Authors:  Hannah Stirton; Neil H Shear; Roni P Dodiuk-Gad
Journal:  Biomedicines       Date:  2022-04-26

4.  The Link between Hypersensitivity Syndrome Reaction Development and Human Herpes Virus-6 Reactivation.

Authors:  Joshua C Pritchett; Radu M Nanau; Manuela G Neuman
Journal:  Int J Hepatol       Date:  2012-05-16

Review 5.  New Insights into Drug Reaction with Eosinophilia and Systemic Symptoms Pathophysiology.

Authors:  Philippe Musette; Baptiste Janela
Journal:  Front Med (Lausanne)       Date:  2017-12-04

Review 6.  Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions.

Authors:  Mari Orime
Journal:  J Immunol Res       Date:  2017-10-31       Impact factor: 4.818

Review 7.  Pharmacogenetics of drug hypersensitivity.

Authors:  Elizabeth J Phillips; Simon A Mallal
Journal:  Pharmacogenomics       Date:  2010-07       Impact factor: 2.533

Review 8.  Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review.

Authors:  Rohini Arora; Rajesh K Pande; Shikha Panwar; Vivek Gupta
Journal:  Indian J Crit Care Med       Date:  2021-05

9.  Structure-Activity-Relationship-Aided Design and Synthesis of xCT Antiporter Inhibitors.

Authors:  Davide Cirillo; Shahin Sarowar; Per Øyvind Enger; Hans-René Bjørsvik
Journal:  ChemMedChem       Date:  2021-05-28       Impact factor: 3.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.